{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:40Z","timestamp":1793192500084,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01520-y","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:21:48Z","timestamp":1732778508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bispecific antibodies in clinical practice: Understanding recent advances\u00a0and\u00a0current\u00a0place in cancer treatment landscape"],"prefix":"10.1007","volume":"25","author":[{"given":"Vaibhav","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1520_CR1","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1056\/NEJMe2208708","volume":"387","author":"M Dan Longo","year":"2022","unstructured":"Dan Longo M, et al. The expanding clinical role of bifunctional antibodies. N Engl J Med. 2022;387:2287\u201390.","journal-title":"N Engl J Med"},{"key":"1520_CR2","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMe2212732","volume":"387","author":"NL Bartlett","year":"2022","unstructured":"Bartlett NL, M.D., et al. Bispecific Antibodies in Lymphoma - Another Win for T cells. N Engl J Med. 2022;387:2285\u20136.","journal-title":"N Engl J Med"},{"key":"1520_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40:481\u201391.","journal-title":"J Clin Oncol"},{"key":"1520_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021;398:1157\u201369.","journal-title":"Lancet"},{"issue":"24","key":"1520_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220.","journal-title":"N Engl J Med"},{"key":"1520_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308.","journal-title":"Lancet"},{"key":"1520_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"1520_CR8","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial. J Clin Oncol. 2023;41(12):2238.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1520_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495.","journal-title":"N Engl J Med"},{"issue":"9","key":"1520_CR10","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259.","journal-title":"Nat Med"},{"issue":"24","key":"1520_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232.","journal-title":"N Engl J Med"},{"issue":"8","key":"1520_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1520_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836.","journal-title":"N Engl J Med"},{"issue":"22","key":"1520_CR14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063.","journal-title":"N Engl J Med"},{"issue":"13","key":"1520_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196.","journal-title":"N Engl J Med"},{"issue":"8","key":"1520_CR16","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432e.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath L, Autio K, et al. A phase 1 study of Acapatamab, a half life extended, PSMA- targeting Bispecific T- cell Engager for metastatic castrate- resistant prostate cancer. Clin Cancer Res. 2024;30(8):1488\u2013500. https:\/\/doi.org\/10.1158\/1078-0432e.CCR-23-2978.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1520_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as second-line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640.","journal-title":"N Engl J Med"},{"issue":"11","key":"1520_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01520-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:44:39Z","timestamp":1764917079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01520-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01520-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"11"}}